Insider Selling: Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Sells 213 Shares of Stock

Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Thomas David Hull III sold 213 shares of the company’s stock in a transaction on Friday, March 21st. The stock was sold at an average price of $48.53, for a total transaction of $10,336.89. Following the transaction, the chief executive officer now owns 40,916 shares of the company’s stock, valued at approximately $1,985,653.48. The trade was a 0.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Thomas David Hull III also recently made the following trade(s):

• On Monday, March 24th, Thomas David Hull III sold 3,000 shares of Kewaunee Scientific stock. The stock was sold at an average price of $45.63, for a total transaction of $136,890.00.
• On Friday, January 10th, Thomas David Hull III sold 1,368 shares of Kewaunee Scientific stock. The shares were sold at an average price of $60.08, for a total value of $82,189.44.
• On Thursday, December 26th, Thomas David Hull III sold 2,000 shares of Kewaunee Scientific stock. The stock was sold at an average price of $63.01, for a total value of $126,020.00.

Kewaunee Scientific Price Performance

Shares of Kewaunee Scientific stock traded down $1.54 during trading on Monday, hitting $44.96. 43,557 shares of the company were exchanged, compared to its average volume of 22,493. Kewaunee Scientific Co. has a fifty-two week low of $30.82 and a fifty-two week high of $71.33. The company has a quick ratio of 2.13, a current ratio of 2.64 and a debt-to-equity ratio of 0.45. The firm has a 50 day moving average price of $57.46 and a 200 day moving average price of $47.68. The stock has a market capitalization of $128.36 million, a price-to-earnings ratio of 7.13 and a beta of 0.71.

Kewaunee Scientific (NASDAQ:KEQU) last released its quarterly earnings results on Wednesday, March 12th. The technology company reported $1.09 earnings per share for the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%. The company had revenue of $67.17 million during the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. De Lisle Partners LLP grew its holdings in shares of Kewaunee Scientific by 36.6% during the third quarter. De Lisle Partners LLP now owns 42,958 shares of the technology company’s stock worth $1,446,000 after buying an additional 11,511 shares in the last quarter. State Street Corp acquired a new stake in Kewaunee Scientific during the third quarter worth approximately $266,000. Barclays PLC purchased a new stake in Kewaunee Scientific in the 3rd quarter worth approximately $121,000. Geode Capital Management LLC grew its stake in Kewaunee Scientific by 8.9% in the 3rd quarter. Geode Capital Management LLC now owns 23,784 shares of the technology company’s stock worth $792,000 after acquiring an additional 1,941 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Kewaunee Scientific by 18,000.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company’s stock valued at $30,000 after acquiring an additional 900 shares during the last quarter. Institutional investors and hedge funds own 32.69% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of Kewaunee Scientific from a “buy” rating to a “hold” rating in a research report on Friday, March 14th.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.